June 5, 2017
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
Read More
March 30, 2017
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
Read More
X